Orgenesis has entered into a collaboration agreement with Savicell Diagnostics to deploy Savicell’s patented ImmunoBiopsy immunometabolism platform. The aim is to develop and validate diagnostic kits for enhanced quality control (QC) and monitoring purposes to be used by Orgenesis in manufacturing and processing of its cell and gene therapies. New assays will be developed to enhance the potency of cell and gene therapies for use within its point-of-care […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!